Pathogen-associated gene discovery workflows for novel antivirulence therapeutic development

Area of Science:

• Microbiology
• Pharmacology
• Genomics

Background:

• Antimicrobial resistance (AMR) necessitates novel therapeutic strategies beyond traditional antibiotics.
• Antivirulence therapeutics offer a promising alternative by targeting bacterial virulence factors, minimizing AMR development and microbiota disruption.
• Pathogen-associated genes (PAGs) represent a largely unexplored reservoir of potential targets for antivirulence drug development.

Purpose of the Study:

• To review current advancements in antivirulence drug research and development.
• To highlight the potential of pathogen-associated genes (PAGs) as novel drug targets.
• To present a comprehensive workflow for discovering antivirulence drugs, from target identification to drug discovery.

Main Methods:

• Review of existing literature on antivirulence drug research and development.
• Identification and characterization of pathogen-associated genes (PAGs).
• Integration of bioinformatic/genomic methods with experimental validation and drug screening platforms.

Main Results:

• Pathogen-associated genes (PAGs), particularly those encoding hypothetical proteins, offer a rich source of novel antivirulence drug targets.
• A systematic workflow combining genomic discovery with experimental validation is crucial for effective antivirulence drug development.
• Integrating computational and experimental approaches enhances the discovery of effective antivirulence therapies.

Conclusions:

• Antivirulence strategies targeting PAGs are a viable approach to combat bacterial infections and mitigate AMR.
• The proposed workflow provides a roadmap for discovering novel antivirulence drugs.
• Further research integrating bioinformatics and experimental characterization is essential for advancing antivirulence drug development.